Sign in

    William M. Greenman

    President and Chief Executive Officer at Cerus Corp
    Board
    Since April 2011
    Age
    57 years
    Education
    Holds a B.A.S. in economics and biological sciences from Stanford University.
    Tenure
    Joined Cerus Corporation in 1995 and progressed through roles including Director of Business Development, Vice President of Business Development, President of Cerus Europe, Senior Vice President of Business Development and Marketing, Chief Business Officer, and became President and Chief Executive Officer in April 2011.

    Also at Cerus Corp

    CMM
    Carol M. Moore
    SVP, Regulatory Affairs and Quality
    CJ
    Chrystal Jensen
    Chief Legal Officer and General Counsel
    KDG
    Kevin D. Green
    Chief Financial Officer

    About

    William M. Greenman is currently 57 years old as of April 2024, reflecting decades of professional growth and dedication in the biotechnology sector. He boasts a strong educational background, holding a B.A.S. in economics and biological sciences from Stanford University, which has laid the foundation for his leadership and strategic vision.

    His career at Cerus Corporation began in 1995 when he joined as Director of Business Development. Over the years, he has advanced through key roles including Vice President of Business Development, President of Cerus Europe, Senior Vice President of Business Development and Marketing, and Chief Business Officer. His significant promotion to President and Chief Executive Officer came in April 2011, marking a milestone in his longstanding tenure with the company.

    Before his remarkable journey at Cerus, he gained valuable industry experience in various marketing and business development roles at Baxter’s Biotech Division and also had a brief stint in venture capital. His broad experience in both executive leadership and board roles, including his involvement with Aduro Biotech, Inc. and Chinook Therapeutics, further underscores his comprehensive expertise in the healthcare and biotechnology sectors.

    $CERS Performance Under William M. Greenman

    Past Roles

    OrganizationRoleDate RangeDetails
    Chinook Therapeutics Board of Directors N/A - August 2023 Tenure ended after the company's acquisition by Novartis AG
    Cerus Corporation Senior Vice President, Business Development and Marketing August 2008 - April 2011 Held prior to becoming CEO
    Cerus Corporation Chief Business Officer April 2010 Held concurrently with other roles
    Cerus Corporation President, Cerus Europe 2006 - August 2008 Focused on European operations
    Cerus Corporation Vice President, Business Development 1999 - 2006 Early leadership role in business development
    Cerus Corporation Director of Business Development 1995 - 1999 Initial role at Cerus
    Baxter's Biotech Division Marketing and Business Development positions 1991 - 1995 Various roles prior to joining Cerus

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$763,750 AnnualFixed annual salary paid for the role as President and Chief Executive Officer
    All Other Compensation$2,372 AnnualComprises Group-term life insurance premiums: $2,322 and Cell phone accessory stipend: $50

    Performance Compensation

    Data from  FY 2023

    Non-Equity Incentive Plan Compensation

    MetricValueDetails
    Target Bonus$539,000 70% of base salary
    Achievement Rate50% Final performance rate determined by the Compensation Committee
    Actual Bonus Payout$269,500 50% of target bonus
    Performance WeightsQuantitative: 50%, Qualitative: 45%, Strategic: 5% Bonus plan is based on a mix of quantitative, qualitative, and strategic goals

    Performance-Based RSU (PRSU) Awards

    MetricValueDetails
    Performance MetricsRevenue & Clinical Trial Enrollment Specific revenue and clinical trial enrollment goals are confidential
    Threshold173,250 shares Minimum performance requirement
    Target192,500 shares Target performance level
    Maximum211,750 shares Maximum cap on award units
    Vesting ConditionsPerformance-based Vesting occurs upon achievement of the performance conditions and continued service over the performance period
    Performance PeriodMar 1, 2023 – Dec 31, 2025 Three-year evaluation period
    Grant DateApril 3, 2023 The date on which the PRSU awards were granted
    Grant Date Fair Value$550,550 each Fair value per PRSU award for Revenue and Clinical Trial categories (Total $1,101,100 for both)
    Grant Date Stock PriceN/ASpecific stock price on the grant date was not provided